STEAP2, a six-transmembrane epithelial antigen of the prostate, is uniformly overexpressed in PRAD and associated with higher Gleason grades and aggressive phenotypes, which is in line with its strong positive correlation with TMBIM6 in this study [31,32,33]. The gene discussed is STEAP2; the disease is prostate adenocarcinoma.